FFO (TTM)

FFO/share (TTM)

FFO (Quarter)

FFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/FFO

Size (ft²)

Occupancy

Alexander’s, Inc. is a real estate investment trust (REIT) engaged in leasing, managing, developing and redeveloping properties. Alexander’s activities are conducted through its manager, Vornado Realty Trust. Alexander’s has seven properties in the greater New York City metropolitan area consisting of: 731 Lexington Avenue office and retail (including Bloomberg, L.P.'s world headquarters), the Rego Center complex in Rego Park, Queens, including the Rego Park I, II, and III retail properties and The Alexander apartment tower, and retail properties located in Paramus, NJ & Flushing, NY.

Alexander's Inc

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

Period: 2023 Q3

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2023 Q4

Years since IPO: 15/15,
FFO Growth: 3/15,
FFO/share Growth: 3/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q1

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q2

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q3

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q4

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q1

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q2

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q3

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q4

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2026 Q1

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2026 Q2

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's FFO

FFO Growth

Assessment of recent increases in FFO per share, indicating profitability

FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer – – Presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026 that further validate a biomarker-driven development strategy for evorpacept – – Strong enrollment momentum in Phase 1 clinical trial of ALX2004 in EGFR expressing solid tumors with initial safety data on-track for 2H 2026 – – Strengthened leadership team with the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Vornado Realty Trust reported second-quarter comparable funds from operations of $0.67 per share, up from $0.56 a year earlier, as leasing gains at its PENN District properties, signage revenue and New York office and retail performance contributed to growth.

Alexander's Q2 Earnings Call Highlights

PARAMUS, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended June 30, 2026 today and reported:

Alexander's Announces Second Quarter Financial Results

PARAMUS, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on August 28, 2026 to stockholders of record on August 10, 2026.

Alexander's Declares Quarterly $4.50 Dividend on Common Shares

PARAMUS, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2026 with the U.S. Securities and Exchange Commission and issue its second quarter earnings release on Monday, August 3, 2026, before the New York Stock Exchange opens.

Alexander's Announces Second Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call

SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 500,000 shares of ALX Oncology's common stock to Michael Listgarten, General Counsel, on June 29, 2026 in connection with the commencement of his employment. Mr. Listgarten's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Listgarten to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif.

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

PARAMUS, N. J. , June 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed a 15-year lease (with renewal options) with Target Corporation at its Rego Park Shopping Center located on Junction Blvd at the Long Island Expressway, in the middle of densely populated Queens, New York.

Alexander’s Leases 135,000 Square Feet to Target at its Rego Park Shopping Center; Center is 99% Leased

PARAMUS, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed a 15-year lease (with renewal options) with Target Corporation at its Rego Park Shopping Center located on Junction Blvd at the Long Island Expressway, in the middle of densely populated Queens, New York.

Alexander's Leases 135,000 Square Feet to Target at its Rego Park Shopping Center; Center is 99% Leased

 ON TRACK FOR MID-2027 TOPLINE DATA READOUT FROM 80 PATIENTS IN THE PHASE 2 ASPEN-09-BREAST CLINICAL TRIAL EVALUATING EVORPACEPT IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER   PRESENTED ENCOURAGING PHASE 1B/2 BREAST CANCER DATA AT ESMO BREAST CANCER 2026 THAT FURTHER VALIDATE A BIOMARKER-DRIVEN DEVELOPMENT STRATEGY FOR EVORPACEPT   STRONG ENROLLMENT MOMENTUM IN PHASE 1 CLINICAL TRIAL OF ALX2004 IN EGFR EXPRESSING SOLID TUMORS WITH INITIAL SAFETY DATA ON-TRACK FOR 2H 2026   STRENGTHENED LEADERSHIP TEAM WITH THE APPOINTMENTS OF SCOTT GARLAND AS CHAIRMAN OF THE BOARD OF DIRECTORS AND MICHAEL LISTGARTEN AS GENERAL COUNSEL  SOUTH SAN FRANCISCO, CALIF., AUG. 06, 2026 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC. ("ALX ONCOLOGY," NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED A CORPORATE UPDATE.

ALX ONCOLOGY REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

PARAMUS, N.J., AUG. 03, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NEW YORK STOCK EXCHANGE: ALX) FILED ITS FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2026 TODAY AND REPORTED:

ALEXANDER'S ANNOUNCES SECOND QUARTER FINANCIAL RESULTS

PARAMUS, N.J., JULY 29, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS DECLARED A REGULAR QUARTERLY DIVIDEND OF $4.50 PER SHARE PAYABLE ON AUGUST 28, 2026 TO STOCKHOLDERS OF RECORD ON AUGUST 10, 2026.

ALEXANDER'S DECLARES QUARTERLY $4.50 DIVIDEND ON COMMON SHARES

PARAMUS, N.J., JULY 21, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) TODAY ANNOUNCED THAT IT WILL FILE ITS QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2026 WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION AND ISSUE ITS SECOND QUARTER EARNINGS RELEASE ON MONDAY, AUGUST 3, 2026, BEFORE THE NEW YORK STOCK EXCHANGE OPENS.

ALEXANDER'S ANNOUNCES SECOND QUARTER EARNINGS RELEASE DATE AND VORNADO REALTY TRUST QUARTERLY CONFERENCE CALL

SOUTH SAN FRANCISCO, CALIF., JUNE 30, 2026 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC. ("ALX ONCOLOGY," NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF ALX ONCOLOGY APPROVED THE GRANTING OF AN INDUCEMENT STOCK OPTION TO PURCHASE A TOTAL OF 500,000 SHARES OF ALX ONCOLOGY'S COMMON STOCK TO MICHAEL LISTGARTEN, GENERAL COUNSEL, ON JUNE 29, 2026 IN CONNECTION WITH THE COMMENCEMENT OF HIS EMPLOYMENT. MR. LISTGARTEN'S INDUCEMENT STOCK OPTION IS SUBJECT TO THE TERMS OF THE ALX ONCOLOGY HOLDINGS INC. 2025 INDUCEMENT EQUITY INCENTIVE PLAN AND RELATED FORMS OF AGREEMENTS, AND WAS GRANTED AS AN INDUCEMENT MATERIAL TO MR. LISTGARTEN TO ENTER INTO EMPLOYMENT WITH ALX ONCOLOGY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ALX ONCOLOGY REPORTS INDUCEMENT GRANT AS PERMITTED BY THE NASDAQ LISTING RULES

STRENGTHENS LEADERSHIP WITH VETERAN EXECUTIVES WITH DECADES OF INDUSTRY EXPERIENCE SCOTT GARLAND SUCCEEDS CO-FOUNDER COREY GOODMAN, PH.D., AFTER MORE THAN A DECADE OF FOUNDATIONAL LEADERSHIP SOUTH SAN FRANCISCO, CALIF.

ALX ONCOLOGY APPOINTS SCOTT GARLAND AS CHAIRMAN OF THE BOARD AND MICHAEL LISTGARTEN AS GENERAL COUNSEL

PARAMUS, N.J., JUNE 29, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) ANNOUNCED TODAY THAT IT HAS COMPLETED A 15-YEAR LEASE (WITH RENEWAL OPTIONS) WITH TARGET CORPORATION AT ITS REGO PARK SHOPPING CENTER LOCATED ON JUNCTION BLVD AT THE LONG ISLAND EXPRESSWAY, IN THE MIDDLE OF DENSELY POPULATED QUEENS, NEW YORK.

ALEXANDER'S LEASES 135,000 SQUARE FEET TO TARGET AT ITS REGO PARK SHOPPING CENTER; CENTER IS 99% LEASED

VANCOUVER, BRITISH COLUMBIA, JUNE 16, 2026 (GLOBE NEWSWIRE) -- GREENRIDGE EXPLORATION INC. (GREENRIDGEOR THE COMPANY) (CSE: GXP | OTC: GXPLF | FRA: HW3), IS PLEASED TO ANNOUNCE THAT THE COMPANY HAS FULFILLED ALL THE OBLIGATIONS OF ITS PROPERTY OPTION AGREEMENT (THE AGREEMENT) TO EARN A 100% LEGAL AND BENEFICIAL INTEREST IN THE CARPENTER LAKE URANIUM PROJECT (CARPENTER LAKE OR THE PROJECT), LOCATED ON THE SOUTHERN MARGIN OF THE ATHABASCA BASIN IN NORTHERN SASKATCHEWAN, CANADA. GREENRIDGE ENTERED INTO THE AGREEMENT IN MAY 2024 WITH ALX RESOURCES CORP. (ALX) AND RENEGADE GOLD INC. (RENEGADE AND TOGETHER WITH ALX, THE OPTIONORS) AND HAS SINCE CARRIED OUT SYSTEMATIC EXPLORATION AT THE PROJECT, INCLUDING DIAMOND DRILLING, IN 2024, 2025 AND 2026.

GREENRIDGE EXPLORATION FULLY EXERCISES OPTION FOR 100% INTEREST IN THE CARPENTER LAKE URANIUM PROJECT IN ATHABASCA BASIN, SASKATCHEWAN

SOUTH SAN FRANCISCO, CALIF., JUNE 01, 2026 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC. ("ALX ONCOLOGY NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED THAT ALX ONCOLOGY LEADERSHIP WILL PARTICIPATE IN A FIRESIDE CHAT PRESENTATION AT THE 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK.

ALX ONCOLOGY TO PRESENT AT THE 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK

PARAMUS, N.J., MAY 28, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) ANNOUNCED TODAY THAT IT HAS COMPLETED THE PREVIOUSLY ANNOUNCED SALE OF ITS REGO PARK I PROPERTY, LOCATED IN QUEENS, NEW YORK, TO NORTHWELL HEALTH, INC.

Alexander's Inc

ALX

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

No items found.

Diversification by Country

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ALX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

No items found.

Diversification by Country

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ALX